MYC and neoplasm: In aggressive B-cell lymphomas, c-MYC-mediated recruitment of EZH2 causes H3K27me3-dependent silencing of the tumor suppressor miR-26a, and c-MYC or EZH2 inhibitors reactivate miR-26a expression in this malignancy [57].